Svasti Haricharan, Ph.D.
Lab Website
Svasti Haricharan's Research Focus
Dr. Haricharan's lab focuses on the role of DNA damage repair in inducing resistance to endocrine therapy in breast cancer, particularly the role of HER2/4 in mismatch repair deficiency, and in identifying early driver mutations in breast cancer formation.
Svasti Haricharan's Bio
Haricharan received her B.Sc from Stella Maris College in Chennai, India, her M.Sc from the University of Leicester, UK , and her PhD in Molecular and Cellular Biology from Baylor College of Medicine. Haricharan completed 2 years of postdoctoral training at MD Anderson Cancer Center studying the effect of mutation load on breast cancer, before moving to Baylor College of Medicine for her second postdoctoral position focused on breast cancer genomics, where she was promoted to Research Assistant Professor. As junior mentored faculty at Baylor College of Medicine, she developed a research program studying non-canonical roles for DNA damage repair defects in cancer. In October 2018, Haricharan joined the faculty at SBP Medical Discovery Institute as an Assistant Professor in the Tumor Microenvironment and Cancer Immunology Program.
Funding awards and collaborative grants
Department of Defense Breast Research Program Breakthrough Award
Susan G Komen Career Catalyst Research Award
Honors and recognition
2013-15: NCI Cancer Prevention Research Training Fellowship
2015-17: SU2C Laura Ziskin Postdoctoral Fellow
Publications
HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer.
Mazumder A, Shiao S, Haricharan S
Endocrinology 2021 Oct 1 ;162(10)
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer.
Punturi NB, Seker S, Devarakonda V, Mazumder A, Kalra R, Chen CH, Li S, Primeau T, Ellis MJ, Kavuri SM, Haricharan S
Nat Commun 2021 May 19 ;12(1):2940
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization.
Sajjadi E, Venetis K, Piciotti R, Invernizzi M, Guerini-Rocco E, Haricharan S, Fusco N
Cancer Cell Int 2021 May 17 ;21(1):266
Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.
Garancher A, Suzuki H, Haricharan S, Chau LQ, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Jones SJM, Moore RA, Mungall AJ, Ma Y, Thiessen N, Li Y, Morcavallo A, Qi L, Kogiso M, Du Y, Baxter P, Henderson JJ, Crawford JR, Levy ML, Olson JM, Cho YJ, Deshpande AJ, Li XN, Chesler L, Marra MA, Wajant H, Becher OJ, Bradley LM, Ware CF, Taylor MD, Wechsler-Reya RJ
Nat Neurosci 2020 Jul ;23(7):842-853
Endocrine therapy resistance: new insights.
Lei JT, Anurag M, Haricharan S, Gou X, Ellis MJ
Breast 2019 Nov ;48 Suppl 1:S26-S30
CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?
Anurag M, Haricharan S, Ellis MJ
Clin Cancer Res 2020 Jan 1 ;26(1):3-5